A primer on evaluation methods for large language models in healthcare
Read the original on arXiv AI →The Flow has not summarised this story yet — read it at arXiv AI.
The Flow has not summarised this story yet — read it at arXiv AI.
arXiv:2609.24516v1 Announce Type: new Abstract: In recent years, large language models (LLMs) have emerged as a popular alternative for evaluation. Often referred to as LLMs as judges (LLJs), these s...
The study evaluates AI-generated summaries for cancer patients using a dual assessment framework that includes human experts and LLM-as-a-judge. Human domain experts—oncology clinicians and patient-facing care staff—assess summary quality on accuracy, clinical relevance, and readability. The research identifies limitations such as omissions and minor inaccuracies, which are then used to iteratively refine prompts, grounding, and safety guardrails.
arXiv:2609.37788v1 Announce Type: cross Abstract: Rubrics support the structured evaluation of language models. We propose a rubric for assessing expressed clinical reasoning in model responses, draw...
arXiv:2409. 07314v3 Announce Type: replace-cross Abstract: While Large Language Models (LLMs) achieve superhuman performance on standardized medical licensing exams, these static benchmarks have become saturated and increasingly disconnected from the functional requirements of clinical workflows.
The study introduces Safety-Focused Evaluation of Scaling (SaFE-Scale) and applies it to RadSaFE-200, a 200-question radiology benchmark with clinician-defined evidence and safety labels. Thirty-four local large language models were tested under six deployment conditions, showing that providing clean clinician-written evidence significantly improved accuracy and reduced high-risk errors and dangerous overconfidence. The results indicate that safety in clinical LLMs depends more on deployment choices than on model size or inference-time compute.
arXiv:2607. 09932v1 Announce Type: cross Abstract: Large language models are increasingly used to summarize clinical trial results for healthcare providers, patients, and payers, but their tendency to hallucinate poses significant risks in this high-stakes context.